Eli Lilly and Company (LLY)

NYQ – Real Time Price. Currency in USD

1220.42

+5.40 (0.44%)

At close: Aug 12, 2026, 3:59 PM EDT

1220.28

-0.14 (-0.01%)

After-hours: Aug 12, 2026, 4:07 PM EDT

10.08.2026

17 S&P 500 companies with growing revenue and profit margins — and some of their stocks are cheap

These companies increased their quarterly sales per share by at least 40% while expanding their gross profit margins and their operating margins.

10.08.2026

3 Beaten-Down Healthcare Stocks to Buy in August

Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.

10.08.2026

UK green lights Lilly's obesity pill

The British medicines ‌regulator on Monday authorised Eli ⁠Lilly's pill Foundayo for weight management and type 2 ‌diabetes, ⁠becoming Europe's first country to ⁠do so.

10.08.2026

Nvidia, Eli Lilly, and Disney Show It's Time to Back the Top Dogs

Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now.

09.08.2026

Top 50 High-Quality Dividend Growth Stocks For August 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify timely, attractive entry points for long-term total return. The universe delivered a 10.44% YTD return through July, closely matching SPY but trailing SCHD, with several individual stocks significantly outperforming. Currently, 40 stocks in the universe offer a forward return estimate of at least 10%, with 25 appearing potentially undervalued based on free cash flow analysis.

08.08.2026

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Eli Lilly leads the GLP-1 market and could remain on top thanks to a deep pipeline. Viking Therapeutics' leading GLP-1 candidate looks very promising.

08.08.2026

Eli Lilly and Company Q2 Earnings Call Highlights

Eli Lilly and Company NYSE: LLY reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance.

Videos

05.08.2026

Negative

Wednesday's Final Takeaways: GOOGL AI Chief Leaves, GLP-1 Boosts LLY

05.08.2026

Positive

Market Close: Stock Rally Fades, Job Growth Weakens, Strong Earnings Boost Eli Lilly 8-5-2026

05.08.2026

Positive

Inside Out: LLY and the Future of Weight Loss Drugs

Press releases

05.08.2026

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Revenue in Q2 2026 increased 48% to $23.0 billion driven primarily by Mounjaro and Zepbound volume. Q2 2026 EPS increased by 26% to $7.94 on a reported basis and increased by 33% to $8.38 on a non-GAAP basis.

03.08.2026

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

INDIANAPOLIS, Aug. 3, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced pancreatic cancer who have received at least one prior systemic therapy and have a KRAS G12C mutation, as determined by an FDA-approved test. Olomorasib is an investigational, potent and highly selective next-generation inhibitor of KRAS G12C.

Eli Lilly and Company (LLY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Eli Lilly and Company (LLY)

17 S&P 500 companies with growing revenue and profit margins — and some of their stocks are cheap